


Short Article

Cell Host & Microbe

Mammalian Lipopolysaccharide Receptors Incorporated into the Retroviral Envelope Augment Virus Transmission

Graphical Abstract



Authors

Jessica Wilks, Egil Lien, Amy N. Jacobson, Michael A. Fischbach, Nilofer Qureshi, Alexander V. Chervonsky, Tatyana V. Golovkina

Correspondence

tgolovki@bsd.uchicago.edu

In Brief

The products of commensal bacteria promote transmission of several unrelated enteric viruses. Wilks et al. find that an orally transmitted retrovirus incorporates mammalian lipopolysaccharide (LPS)-binding factors into its membrane, which bind LPS and counteract the anti-viral immune response. Thus, viruses exploit mammalian receptors for bacterial products to achieve efficient transmission.

Highlights

- The enveloped retrovirus MMTV acquires host LPS-binding factors during egress
- LPS-binding factors incorporated into the viral membrane enable MMTV to bind LPS
- Virally bound LPS augments virus transmission
- MMTV binding augments the immunopotency of commensal LPS



Mammalian Lipopolysaccharide Receptors Incorporated into the Retroviral Envelope Augment Virus Transmission

Jessica Wilks,^{1,7} Egil Lien,^{2,3} Amy N. Jacobson,⁴ Michael A. Fischbach,⁴ Nilofer Qureshi,⁵ Alexander V. Chervonsky,⁶ and Tatyana V. Golovkina^{1,*}

¹Department of Microbiology, The University of Chicago, Chicago, IL 60637, USA

²Division of Infectious Diseases and Immunology, Program in Innate Immunity, Department of Medicine, University of Massachusetts, Worcester, MA 01605, USA

³Center of Molecular Inflammation Research, Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology (NTNU), 7491 Trondheim, Norway

⁴Department of Bioengineering and Therapeutic Sciences and California Institute of Quantitative Biosciences, University of California, San Francisco, San Francisco, CA 94158, USA

⁵Shock and Trauma Research Center, Medical School, University of Missouri, Kansas City, MO 64108, USA

⁶Department of Pathology, The University of Chicago, Chicago, IL 60637, USA

⁷Present address: Department of Biology, Tufts University, Medford, MA 02155, USA

*Correspondence: tgolovki@bsd.uchicago.edu

<http://dx.doi.org/10.1016/j.chom.2015.09.005>

SUMMARY

The orally transmitted retrovirus mouse mammary tumor virus (MMTV) requires the intestinal microbiota for persistence. Virion-associated lipopolysaccharide (LPS) activates Toll-like receptor 4 (TLR4), stimulating production of the immunosuppressive cytokine IL-10 and MMTV evasion of host immunity. However, the mechanisms by which MMTV associates with LPS remain unknown. We find that the viral envelope contains the mammalian LPS-binding factors CD14, TLR4, and MD-2, which, in conjunction with LPS-binding protein (LBP), bind LPS to the virus and augment transmission. MMTV isolated from infected mice lacking these LBPs cannot engage LPS or stimulate TLR4 and have a transmission defect. Furthermore, MMTV incorporation of a weak agonist LPS from *Bacteroides*, a prevalent LPS source in the gut, significantly enhances the ability of this LPS to stimulate TLR4, suggesting that MMTV intensifies these immunostimulatory properties. Thus, an orally transmitted retrovirus can capture, modify, and exploit mammalian receptors for bacterial ligands to ensure successful transmission.

INTRODUCTION

Mouse mammary tumor virus (MMTV) is a retrovirus that is transmitted as an endogenous, stably integrated provirus (*Mtv*) or as an exogenous virus (Goff, 2007). Exogenous MMTV is spread via the milk of infected females and is acquired by suckling pups. In the gut, the virus transcytoses through M cells in Peyer's patches (Golovkina et al., 1999) and infects the underlying lymphoid cells, including T and B lymphocytes. Infected T and B cells traffic to

the mammary gland and pass the virus to the mammary gland epithelia (Finke and Acha-Orbea, 2001). During lactation, the virus is secreted into the milk and is transmitted to the progeny.

Persistence of the virus requires commensal bacteria and functional TLR4, as the virus is eliminated in both TLR4-deficient specific-pathogen-free (SPF) (Jude et al., 2003) and wild-type (WT) germ-free (GF) mice (Kane et al., 2011). A series of genetic and biochemical experiments established that, after infiltrating the host, the virus cloaks itself in lipopolysaccharide (LPS). The LPS-associated virus activates TLR4, which leads to IL-6-mediated production of the immunosuppressive cytokine IL-10 and blockage of the antiviral response (Jude et al., 2003; Kane et al., 2011). However, the nature of the virus-LPS interaction has remained unknown. Here we report that mammalian LPS receptors are integrated in the viral envelope and bind LPS, thus enabling the virus to activate the immune evasion pathway.

RESULTS

To address whether MMTV directly binds LPS, a modified capture ELISA was used. Both anti-envelope (Env) glycoprotein antibodies (Abs) and biotinylated LPS detected plate-bound MMTV virions equally well (Figure S1), suggesting the virions directly interact with LPS.

Mammals have multiple LPS-binding proteins (LBPs); some transfer LPS to other proteins, while others are directly involved in transmitting LPS-induced signals (Park and Lee, 2013). Specifically, the membrane-anchored protein CD14 binds LPS and transfers it to the MD-2-TLR4 complex (Viriyakosol et al., 2001). MD-2 directly binds LPS, and LPS-bound MD-2 triggers TLR4 dimerization and activation of downstream signaling (Park et al., 2009). Notably, in the absence of TLR4, MD-2 is not present on the cell surface. MMTV, an enveloped retrovirus, targets cells that express and display these LBPs (Lee et al., 2009; Miyake, 2006; Figure S2). Thus, we proposed that the virus acquires these proteins from the host and utilizes them to bind




Figure 1. Mammalian LPS-Binding Receptors Are Present in MMTV Virions

(A) MMTV virions isolated from the milk of B6 wild-type (WT) and $TLR4^{-/-}$ mice were captured either by an anti-mouse TLR4 or anti-gp36Env Abs and detected with biotinylated anti-gp36Env Abs. Error bars represent the SE of three independent experiments. Significance was calculated using a two-sample t test ($*p < 0.03$).

(B) Western blot of proteins from virions purified from the milk of B6 (WT) and $CD14^{-/-}$ females. The same density fraction isolated from uninfected milk (MMTV⁻) was used as a negative control. Anti-mouse CD14 Abs and anti-gp52Env Abs were used to detect CD14 and viral Env, respectively. Mouse CD14 recombinant protein was used as a positive control for anti-CD14 Abs.


(C) Immunogold labeling of MMTV virions. (Top) MMTV virions purified from B6 (WT) (a, b, c, and d) or $CD14^{-/-}$ (e and f) mouse milk were stained with anti-gp52Env Abs followed by anti-mouse Ab coupled to gold particles (b and f) or anti-mouse Ab alone (a) or anti-CD14 Ab followed by anti-rat Ab coupled to gold particles (d and e) or anti-rat Abs alone (c). (Bottom) Quantification of three independent experiments with over 50 virions examined per condition in each experiment. Error bars represent the SE.

(D) MMTV virions isolated from the milk of mice lacking CD14, LBP, MD-2, or TLR4 and from animals deficient in all four factors were captured with anti-gp36Env Abs bound to plastic. The ELISA was developed either with biotinylated LPS (*E. Coli*, serotype EH100) (top) or anti-gp36Env Abs (bottom). Error bars represent SE of three independent experiments. Significance was calculated using a two-sample t test ($**p < 0.001$).

LPS. In fact, both TLR4 and CD14 were detected on purified MMTV virions (Figures 1A–1C), supporting this idea.

To investigate the role of the mammalian LPS-binding machinery in viral acquisition of LPS, we used a genetic approach. WT females and females devoid of MD-2, TLR4, CD14, and another well-characterized LPS-binding factor, LBP (Park et al., 2009),

were infected with MMTV via intraperitoneal injection as adults. The virions isolated from their milk were subjected to the LPS-binding assay. Whereas virus titers were comparable among all isolates (Figure 1D, bottom), virions produced by both $TLR4^{-/-}$ and $MD-2^{-/-}$ females exhibited a significant reduction in LPS binding (Figure 1D, top). This reduction was not observed






Figure 3. MMTV Binds the Lipid A Component of LPS from Diverse Species and Enables Agonist LPS to Resist Inhibition by an Antagonist LPS

(A) LPS-free MMTV from GF MyD88/TLR4 double-deficient mice was incubated with 40 ng/ml lipid A (*E. coli*, serotype R515) (*E.c.*) or *R. sphaeroides* (*R.s.*) and pelleted through a 30% sucrose cushion. The amount of bound endotoxin was quantified by the LAL assay (left). The ability of virus-bound or free lipid A (normalized to 1 ng/ml via the LAL assay) to stimulate IL-6 production by B6 (WT) splenocytes was measured by ELISA (right). Neither *E.c.* or *R.s.* lipid A elicit IL-6 in MD-2^{-/-} splenocytes. Error bars represent SE of three independent experiments. Significance was calculated using a two-sample t test. NS, non-significant.

(B) LPS from *E. coli* serotype 055:B5 (at 5, 50, and 100 ng/ml) or intact SPF-MMTV virions (at 5 ng/ml endotoxin) was added to B6 splenocytes alone or together with increasing concentration of *R.s.* lipid A. IL-6 in tissue culture supernatants was quantified by ELISA 16 hr later. X is the factor by which *R.s.* lipid A concentration was increased relative to *E.c.* LPS. Error bars represent SE of three independent experiments. Significance was calculated using a paired t test (* $p < 0.05$).

mice was incubated with lipid A from either *Escherichia coli* (strong TLR4 agonist [Raetz and Whitfield, 2002]) or *Rhodobacter (R) sphaeroides* (TLR4 antagonist [Kutuzova et al., 2001]). MMTV bound both *E. coli* and *R. sphaeroides* lipid A to an equal degree (Figure 3A). However, only virus-bound *E. coli* lipid A activated TLR4 signaling (Figure 3A). Thus, MMTV does not discriminate between agonist and antagonist LPS/lipid A types for binding, but requires a TLR4 agonist to trigger TLR4 signaling.

MMTV-bound LPS is more immunopotent than virus-free LPS (Kane et al., 2011), indicating that binding of LPS to the viral membrane amplifies LPS-induced TLR4 activation. With this in mind and recognizing that *R. sphaeroides* lipid A antagonizes activation of TLR4 by agonist LPS (Kutuzova et al., 2001), we

sought to determine whether virally bound LPS was protected from this inhibition. Indeed, *R. sphaeroides* lipid A blocked TLR4 activation by free *E. coli* LPS, but virus-bound LPS resisted this inhibition (Figure 3B). As competitive inhibition of free LPS by *R. sphaeroides* lipid A is concentration dependent (Manthey et al., 1993), the most parsimonious explanation for this result is that binding of LPS to the virion increases the effective local concentration, making MMTV-bound LPS more resistant to inhibition by *R. sphaeroides* lipid A.

The majority of Gram-negative commensals that populate the mouse and healthy human gut are of the *Bacteroides* genus (Human Microbiome Project Consortium, 2012) and synthesize relatively weak TLR4 agonists (Figure 4A). Since MMTV must activate TLR4 to propagate within the host, we hypothesized that the virus must potentiate weak agonist LPS. First, it was determined that MMTV binds physiologically relevant LPS from the human commensal *Bacteroides thetaioamicron* (*B. theta*) to the same extent as *E. coli* LPS, one of the strongest TLR4 agonists (Figure 4B). Second, GF-MMTV virions bound to *B. theta* LPS significantly strengthened the immunopotency of this commensal ligand similar to *E. coli* LPS (Figure 4C). Moreover, this phenomenon was observed with LPS species purified directly from MMTV virions (Figure 4D), suggesting that MMTV has the ability to intensify the immunostimulatory properties of agonistic commensal LPS found in the mouse gut.

Internalization of Gram-negative bacteria or LPS by innate immune cells activates a non-canonical inflammasome pathway (Kayagaki et al., 2013). This activation leads to the production and secretion of the inflammatory cytokine IL-1 β , which is known to induce IL-6 (Cahill and Rogers, 2008). To determine whether the non-canonical inflammasome pathway was responsible for the increased immunopotency of virus-bound LPS, we examined virus-elicited IL-6 induction in WT and caspase 1/4-deficient mice, which lack both canonical and non-canonical pathways (Figure 4E). Virus-bound LPS maintained its immunopotency in caspase1/4-deficient splenocytes, suggesting that inflammasome-dependent activation does not explain the enhanced immunopotency of virus-bound LPS.

DISCUSSION

Although it has been noted previously that enveloped viruses acquire host proteins as they bud from the cell (Bubbers and Lilly, 1977; Cantin et al., 2005), few studies have linked the significance of this incorporation to virus replication, transmission, and pathogenesis. HIV-1 selectively incorporates the MHC class II glycoprotein within its membrane and uses it to accelerate entry into human T lymphocytes (Bastiani et al., 1997; Cantin et al., 1997). HTLV-1 displays the complement regulatory proteins CD59 and CD55 on its surface to evade complement-mediated lysis (Spear et al., 1995). In addition, virion-associated MHC class I and class II molecules impact the ability of HIV virions to trigger cell death (Esser et al., 2001). In the case of both HIV-1 and HTLV-1, however, the effects of the host-derived membrane proteins on virus infectivity and pathogenesis were demonstrated only in vitro. In this study, we show that incorporation of mammalian LBPs by an enveloped retrovirus enables the virus to bind LPS and evade the anti-retroviral immune response.




Figure 4. MMTV Augments the Immunopotency of Commensal LPS

(A) The immunostimulatory properties of LPS from *B. theta* and *E. coli* (serotype 055:B5) were compared by IL-6 ELISA after the addition to B6 (WT) and MD-2^{-/-} splenocytes. Error bars represent SE of three independent experiments. Significance was calculated using a two-sample t test (***p* < 0.001).

(B) Binding of biotinylated *B. theta* and *E. coli* (serotype O26) LPS by SPF-MMTV virions captured to plastic with anti-gp36Env Abs was measured in serial dilutions. Error bars represent SE of three independent experiments. Significance was calculated using a two-way ANOVA. NS, non-significant.

(C) *B. theta* or *E. coli* (serotype O26) LPS (at 40 ng/ml endotoxin) was incubated with or without GF-MMTV and spun down via 30% sucrose cushion. Endotoxin levels were measured in pelleted fractions using LAL assay. Fractions with no virus added had no detectable LPS (not shown). Virus-LPS pelleted fractions were added to B6 splenocytes at an endotoxin concentration of 71 pg/ml. The amount of secreted IL-6 was measured in tissue culture supernatants 16 hr later. In separate cultures, virus-free *B. theta* and *E. coli* LPS were added to B6 splenocytes at the same endotoxin concentration. Error bars represent SE of three independent experiments. Significance was calculated using a paired t test (**p* < 0.03 and ***p* < 0.001).

(D) LPS species isolated from SPF-MMTV virions were added to B6 splenocytes as free form (viral LPS) or bound to SPF-MMTV virions at 35 pg/ml. The amount of secreted IL-6 was used as a readout for TLR4 activation. Error bars represent SE of three independent experiments. Significance was calculated using a paired t test (**p* < 0.03).

(E) IL-6 secretion elicited by SPF-MMTV virions in B6 (WT), Caspase 1/4^{-/-} (Caspase 1/4^{-/-}), or MD-2^{-/-} (MD-2^{-/-}) splenocytes or by *E. coli* (serotype 055:B5) LPS from Sigma (S) or Enzo Life Sciences (E) was measured by ELISA. Endotoxin concentration of 1 ng/ml in all samples was verified by the LAL assay. Error bars represent SE of three independent experiments. Significance was calculated using a paired t test (***p* < 0.001).

The most abundant commensal Gram-negative bacterial species within the human and mouse gastrointestinal tract produce LPS that are weak TLR4 agonists (Human Microbiome Project Consortium, 2012). However, when MMTV binds commensal LPS derived from *B. theta*, it strengthens this LPS immunopotency to such an extent that it exceeds the immunopotency of *E. coli* LPS, a potent TLR4 agonist (Figure 4C). How the virus modulates LPS potency remains to be elucidated and will require further investigation. Nevertheless, a few possibilities can be considered. First, LPS aggregates on the viral surface might strengthen TLR4 activation, as aggregated but not monomeric endotoxin activates TLR4 signaling at similar concentrations (Müller et al., 2003). Second, virion bound LPS may have a greater effective concentration than free LPS, resulting in enhanced immunopotency. Third, delivery of LPS bound to the surface of the viral particle stabilizes or prolongs the ligand's interaction with

the cell membrane, facilitating dimerization of MD-2-TLR4 complexes. The latter events potentially can occur on the cell surface or inside the endocytic compartment where functional TLR4 also is located (Kagan et al., 2008; Tanimura et al., 2008).

The phenomenon of LPS exploitation is not restricted to MMTV, as other enteric viruses from completely different genera, such as poliovirus, also utilize LPS to enhance their environmental fitness and infectivity (Kuss et al., 2011; Robinson et al., 2014). Many non-enveloped enteric viruses target cells that express LBPs (Iwasaki et al., 2002; Neal et al., 2006), and some were reported to encase themselves within the host cell membrane (Chen et al., 2015; Feng et al., 2013). Thus, it is possible that even naked viruses could potentially exploit host LPS receptors for their benefit. Further studies of this phenomenon may lead to approaches for the prevention and treatment of some viral infections.

EXPERIMENTAL PROCEDURES

Mice

All animals were bred and maintained at the animal facility of The University of Chicago. SPF MMTV-infected and uninfected C3H/HeN were maintained in our colony. TLR4^{-/-} C57BL10/ScNJ (Poltorak et al., 1998), B6.CD14^{-/-} (Moore et al., 2000), B6.IL-1R1^{-/-} (Glaccum et al., 1997), BALB/c.J.LBP^{-/-} (Jack et al., 1997), B6.Caspase 1/4^{-/-} (Kuida et al., 1995), BALB/c.J, and B6 mice were obtained from The Jackson Laboratory. B6.MD-2^{-/-} mice (Nagai et al., 2002) were crossed to B6 mice for four generations before the MD-2^{-/-} was fixed at homozygosity. BALB/c.J.LBP^{-/-} were crossed to B6 mice for six generations and then crossed to B6.CD14/MD-2/TLR4 triple-deficient mice and intercrossed to generate B6.LBP/CD14/MD-2/TLR4 quadruple-deficient mice. GF C3H/HeN.MyD88/TLR4 double-deficient mice have been reported previously (Kane et al., 2011). The studies described here were reviewed and approved by the Animal Care and Use Committee at The University of Chicago.

Detection of TLR4 on MMTV Virions

MMTV(LA) viral variant (Golovkina et al., 1997) was used in these studies. A capture ELISA was developed to detect TLR4 in virions. Briefly, anti-mouse TLR4 Abs (BioLegend) and anti-gp36Env Ab (Purdy et al., 2003) were bound to a 96-well plate overnight. After blocking, purified virions were added to the capture Abs and the reactions were developed with biotinylated anti-gp36Env Abs.

Detection of CD14 in Purified Virions

MMTV virions isolated from the milk of infected B6 and B6.CD14^{-/-} mice, as well as virus density fractions isolated from the milk of uninfected B6 females, were subjected to western blot analysis using anti-mouse CD14 (Santa Cruz Biotechnology) and anti-gp52Env Abs (Purdy et al., 2003).

Transmission Electron Microscopy

Purified milk-borne virions were placed on glow discharge carbon-coated gold grids and incubated with either mouse anti-gp52Env or rat anti-CD14 Abs followed by anti-mouse or anti-rat Abs coupled to gold-conjugated Abs, respectively. Samples were fixed with glutaraldehyde and stained with uranyl acetate and examined under 300KV at FEI Tecnai F30.

MMTV-LPS Capture ELISA

Anti-gp36Env Abs were bound to 96-well plates and incubated with purified SPF-MMTV virions. ELISA was developed with either biotinylated LPS or biotinylated anti-gp36Env Abs.

MMTV Infection

To compare transmission of MD-2⁺ and MD-2⁻ virions, as well as LBP⁻ and LPB⁺ virions, newborn B6 mice were allowed to suckle on infected WT, MD-2^{-/-}, or LBP^{-/-} females. Deletion of SAg-cognate T cells was used as a readout for MMTV infection, and qPCR was used to quantify viral titers.

LPS Binding to GF-MMTV Virions

Binding of TLR4/MyD88 double-deficient GF-MMTV virions to *E. coli* lipid A, *R. sphaeroides* lipid A, *B. theta* LPS, or *E. coli* LPS was performed as described previously (Kane et al., 2011). Endotoxin concentration was quantified via Limulus amoebocyte lysate (LAL) assay.

SUPPLEMENTAL INFORMATION

Supplemental Information includes Supplemental Experimental Procedures and three figures and can be found with this article online at <http://dx.doi.org/10.1016/j.chom.2015.09.005>.

AUTHOR CONTRIBUTIONS

J.W. produced all LPS-binding-factor-deficient mice and performed most of the experiments. T.V.G. performed electron microscopy and western blot analysis. A.N.J. and M.A.F. purified *B. theta* LPS. N.Q. and E.L. purified *R. sphaeroides* lipid A. E.L. and A.V.C. contributed to experimental design.

J.W. and T.V.G. wrote the manuscript. T.V.G. conceived the project and analyzed the results. All authors discussed the results and commented on the manuscript.

ACKNOWLEDGMENTS

The authors are thankful to Dr. Betty R. Theriault, Alan Vest, and Kristin Kolar for their help in monitoring the gnotobiotic animals; Helen Beilinson and Felicity Deiss for help in genotyping mice; and the T.V.G. laboratory, A.V.C. laboratory, and Howard Shuman for helpful discussions. This work was supported by the NIH/National Institute of Allergy and Infectious Diseases (NIAID) grant AI090084 to T.V.G., T32 AI007090 to J.W., NIH grant AI075305, the Research Council of Norway and the Norwegian Cancer Society to E.L., NIH grant DP2 OD007290 to M.A.F., and the National Science Foundation (NSF) grant 1144247 to A.N.J. This work also was supported by P30 DK42086 grant to the Digestive Diseases Research Core Center (DDRCC, University of Chicago); P30 CA014599 grant to The University of Chicago; the Sandler Family Foundation, the Gordon and Betty Moore Foundation, and P30 CA082103; and DE-AC02-05CH11231 to the University of California, San Francisco.

Received: May 5, 2015

Revised: August 23, 2015

Accepted: September 11, 2015

Published: October 14, 2015

REFERENCES

- Bastiani, L., Laal, S., Kim, M., and Zolla-Pazner, S. (1997). Host cell-dependent alterations in envelope components of human immunodeficiency virus type 1 virions. *J. Virol.* 71, 3444–3450.
- Bubbers, J.E., and Lilly, F. (1977). Selective incorporation of H-2 antigenic determinants into Friend virus particles. *Nature* 266, 458–459.
- Cahill, C.M., and Rogers, J.T. (2008). Interleukin (IL) 1beta induction of IL-6 is mediated by a novel phosphatidylinositol 3-kinase-dependent AKT/IkappaB kinase alpha pathway targeting activator protein-1. *J. Biol. Chem.* 283, 25900–25912.
- Cantin, R., Fortin, J.F., Lamontagne, G., and Tremblay, M. (1997). The presence of host-derived HLA-DR1 on human immunodeficiency virus type 1 increases viral infectivity. *J. Virol.* 71, 1922–1930.
- Cantin, R., Méthot, S., and Tremblay, M.J. (2005). Plunder and stowaways: incorporation of cellular proteins by enveloped viruses. *J. Virol.* 79, 6577–6587.
- Chen, Y.-H., Du, W., Hagemeyer, M.C., Takvorian, P.M., Pau, C., Cali, A., Brantner, C.A., Stempinski, E.S., Connelly, P.S., Ma, H.-C., et al. (2015). Phosphatidylserine vesicles enable efficient en bloc transmission of enteroviruses. *Cell* 160, 619–630.
- Esser, M.T., Graham, D.R., Coren, L.V., Trubey, C.M., Bess, J.W., Jr., Arthur, L.O., Ott, D.E., and Lifson, J.D. (2001). Differential incorporation of CD45, CD80 (B7-1), CD86 (B7-2), and major histocompatibility complex class I and II molecules into human immunodeficiency virus type 1 virions and microvesicles: implications for viral pathogenesis and immune regulation. *J. Virol.* 75, 6173–6182.
- Feng, Z., Hensley, L., McKnight, K.L., Hu, F., Madden, V., Ping, L., Jeong, S.-H., Walker, C., Lanford, R.E., and Lemon, S.M. (2013). A pathogenic picornavirus acquires an envelope by hijacking cellular membranes. *Nature* 496, 367–371.
- Finke, D., and Acha-Orbea, H. (2001). Differential migration of in vivo primed B and T lymphocytes to lymphoid and non-lymphoid organs. *Eur. J. Immunol.* 31, 2603–2611.
- Glaccum, M.B., Stocking, K.L., Charrier, K., Smith, J.L., Willis, C.R., Maliszewski, C., Livingston, D.J., Peschon, J.J., and Morrissey, P.J. (1997). Phenotypic and functional characterization of mice that lack the type I receptor for IL-1. *J. Immunol.* 159, 3364–3371.
- Goff, S.P. (2007). Retroviridae: The viruses and their replication. In *Fields Virology*, D.M. Knipe and P.M. Howley, eds. (Philadelphia, PA: Lippincott Williams and Wilkins, a Wolters Kluwer Business), pp. 1999–2070.

- Golovkina, T.V., Piazzon, I., Nepomnaschy, I., Buggiano, V., de Olano Vela, M., and Ross, S.R. (1997). Generation of a tumorigenic milk-borne mouse mammary tumor virus by recombination between endogenous and exogenous viruses. *J. Virol.* *71*, 3895–3903.
- Golovkina, T.V., Shlomchik, M., Hannum, L., and Chervonsky, A. (1999). Organogenic role of B lymphocytes in mucosal immunity. *Science* *286*, 1965–1968.
- Gutsmann, T., Müller, M., Carroll, S.F., MacKenzie, R.C., Wiese, A., and Seydel, U. (2001). Dual role of lipopolysaccharide (LPS)-binding protein in neutralization of LPS and enhancement of LPS-induced activation of mononuclear cells. *Infect. Immun.* *69*, 6942–6950.
- Hailman, E., Lichenstein, H.S., Wurfel, M.M., Miller, D.S., Johnson, D.A., Kelley, M., Busse, L.A., Zukowski, M.M., and Wright, S.D. (1994). Lipopolysaccharide (LPS)-binding protein accelerates the binding of LPS to CD14. *J. Exp. Med.* *179*, 269–277.
- Human Microbiome Project Consortium (2012). Structure, function and diversity of the healthy human microbiome. *Nature* *486*, 207–214.
- Iwasaki, A., Welker, R., Mueller, S., Linehan, M., Nomoto, A., and Wimmer, E. (2002). Immunofluorescence analysis of poliovirus receptor expression in Peyer's patches of humans, primates, and CD155 transgenic mice: implications for poliovirus infection. *J. Infect. Dis.* *186*, 585–592.
- Jack, R.S., Fan, X., Bernheiden, M., Rune, G., Ehlers, M., Weber, A., Kirsch, G., Mentel, R., Füll, B., Freudenberg, M., et al. (1997). Lipopolysaccharide-binding protein is required to combat a murine gram-negative bacterial infection. *Nature* *389*, 742–745.
- Jude, B.A., Pobežinskaya, Y., Bishop, J., Parke, S., Medzhitov, R.M., Chervonsky, A.V., and Golovkina, T.V. (2003). Subversion of the innate immune system by a retrovirus. *Nat. Immunol.* *4*, 573–578.
- Kagan, J.C., Su, T., Horng, T., Chow, A., Akira, S., and Medzhitov, R. (2008). TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-beta. *Nat. Immunol.* *9*, 361–368.
- Kane, M., Case, L.K., Kopaskie, K., Kozlova, A., MacDearmid, C., Chervonsky, A.V., and Golovkina, T.V. (2011). Successful transmission of a retrovirus depends on the commensal microbiota. *Science* *334*, 245–249.
- Kayagaki, N., Wong, M.T., Stowe, I.B., Ramani, S.R., Gonzalez, L.C., Akashi-Takamura, S., Miyake, K., Zhang, J., Lee, W.P., Muszyński, A., et al. (2013). Noncanonical inflammasome activation by intracellular LPS independent of TLR4. *Science* *341*, 1246–1249.
- Kuida, K., Lippke, J.A., Ku, G., Harding, M.W., Livingston, D.J., Su, M.S., and Flavell, R.A. (1995). Altered cytokine export and apoptosis in mice deficient in interleukin-1 beta converting enzyme. *Science* *267*, 2000–2003.
- Kuss, S.K., Best, G.T., Etheredge, C.A., Pruijssers, A.J., Frierson, J.M., Hooper, L.V., Dermody, T.S., and Pfeiffer, J.K. (2011). Intestinal microbiota promote enteric virus replication and systemic pathogenesis. *Science* *334*, 249–252.
- Kutuzova, G.D., Albrecht, R.M., Erickson, C.M., and Qureshi, N. (2001). Diphosphoryl lipid A from *Rhodobacter sphaeroides* blocks the binding and internalization of lipopolysaccharide in RAW 264.7 cells. *J. Immunol.* *167*, 482–489.
- Lee, S.-H., Hong, B., Sharabi, A., Huang, X.F., and Chen, S.-Y. (2009). Embryonic stem cells and mammary luminal progenitors directly sense and respond to microbial products. *Stem Cells* *27*, 1604–1615.
- MacDearmid, C.C., Case, L.K., Starling, C.L., and Golovkina, T.V. (2006). Gradual elimination of retroviruses in YBR/EI mice. *J. Virol.* *80*, 2206–2215.
- Manthey, C.L., Perera, P.Y., Qureshi, N., Stütz, P.L., Hamilton, T.A., and Vogel, S.N. (1993). Modulation of lipopolysaccharide-induced macrophage gene expression by *Rhodobacter sphaeroides* lipid A and SDZ 880.431. *Infect. Immun.* *61*, 3518–3526.
- Marrack, P., Kushnir, E., and Kappler, J. (1991). A maternally inherited superantigen encoded by a mammary tumour virus. *Nature* *349*, 524–526.
- Miyake, K. (2006). Roles for accessory molecules in microbial recognition by Toll-like receptors. *J. Endotoxin Res.* *12*, 195–204.
- Moore, K.J., Andersson, L.P., Ingalls, R.R., Monks, B.G., Li, R., Arnaout, M.A., Golenbock, D.T., and Freeman, M.W. (2000). Divergent response to LPS and bacteria in CD14-deficient murine macrophages. *J. Immunol.* *165*, 4272–4280.
- Müller, M., Scheel, O., Lindner, B., Gutsmann, T., and Seydel, U. (2003). The role of membrane-bound LBP, endotoxin aggregates, and the MaxiK channel in LPS-induced cell activation. *J. Endotoxin Res.* *9*, 181–186.
- Nagai, Y., Akashi, S., Nagafuku, M., Ogata, M., Iwakura, Y., Akira, S., Kitamura, T., Kosugi, A., Kimoto, M., and Miyake, K. (2002). Essential role of MD-2 in LPS responsiveness and TLR4 distribution. *Nat. Immunol.* *3*, 667–672.
- Neal, M.D., Leaphart, C., Levy, R., Prince, J., Billiar, T.R., Watkins, S., Li, J., Cetin, S., Ford, H., Schreiber, A., and Hackam, D.J. (2006). Enterocyte TLR4 mediates phagocytosis and translocation of bacteria across the intestinal barrier. *J. Immunol.* *176*, 3070–3079.
- Park, B.S., and Lee, J.-O. (2013). Recognition of lipopolysaccharide pattern by TLR4 complexes. *Exp. Mol. Med.* *45*, e66.
- Park, B.S., Song, D.H., Kim, H.M., Choi, B.-S., Lee, H., and Lee, J.-O. (2009). The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. *Nature* *458*, 1191–1195.
- Poltorak, A., He, X., Smirnova, I., Liu, M.Y., Van Huffel, C., Du, X., Birdwell, D., Alejos, E., Silva, M., Galanos, C., et al. (1998). Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. *Science* *282*, 2085–2088.
- Purdy, A., Case, L., Duvall, M., Overstrom-Coleman, M., Monnier, N., Chervonsky, A., and Golovkina, T. (2003). Unique resistance of I/LnJ mice to a retrovirus is due to sustained interferon gamma-dependent production of virus-neutralizing antibodies. *J. Exp. Med.* *197*, 233–243.
- Raetz, C.R.H., and Whitfield, C. (2002). Lipopolysaccharide endotoxins. *Annu. Rev. Biochem.* *71*, 635–700.
- Raetz, C.R.H., Reynolds, C.M., Trent, M.S., and Bishop, R.E. (2007). Lipid A modification systems in gram-negative bacteria. *Annu. Rev. Biochem.* *76*, 295–329.
- Robinson, C.M., Jesudhasan, P.R., and Pfeiffer, J.K. (2014). Bacterial lipopolysaccharide binding enhances virion stability and promotes environmental fitness of an enteric virus. *Cell Host Microbe* *15*, 36–46.
- Ross, S.R. (2008). MMTV infectious cycle and the contribution of virus-encoded proteins to transformation of mammary tissue. *J. Mammary Gland Biol. Neoplasia* *13*, 299–307.
- Spear, G.T., Lurain, N.S., Parker, C.J., Ghassemi, M., Payne, G.H., and Saifuddin, M. (1995). Host cell-derived complement control proteins CD55 and CD59 are incorporated into the virions of two unrelated enveloped viruses. Human T cell leukemia/lymphoma virus type I (HTLV-I) and human cytomegalovirus (HCMV). *J. Immunol.* *155*, 4376–4381.
- Tanimura, N., Saitoh, S., Matsumoto, F., Akashi-Takamura, S., and Miyake, K. (2008). Roles for LPS-dependent interaction and relocation of TLR4 and TRAM in TRIF-signaling. *Biochem. Biophys. Res. Commun.* *368*, 94–99.
- Tobias, P.S., Soldau, K., Gegner, J.A., Mintz, D., and Ulevitch, R.J. (1995). Lipopolysaccharide binding protein-mediated complexation of lipopolysaccharide with soluble CD14. *J. Biol. Chem.* *270*, 10482–10488.
- Trent, M.S., Stead, C.M., Tran, A.X., and Hankins, J.V. (2006). Diversity of endotoxin and its impact on pathogenesis. *J. Endotoxin Res.* *12*, 205–223.
- Viriyakosol, S., Tobias, P.S., Kitchens, R.L., and Kirkland, T.N. (2001). MD-2 binds to bacterial lipopolysaccharide. *J. Biol. Chem.* *276*, 38044–38051.